Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.

Shao-Wen WangTsung-Han HsiehYu-Ming ChengChia-Chi WangJia-Horng Kao

Published in: Hepatology international (2024)

In this large population-based study, cryptogenic SLD, the excluded group, occupy only 3.5% in NAFLD patients. It has lower liver and atherosclerotic risks than MASLD, supporting its exclusion from NAFLD and justifying the rationale for the new disease name and diagnostic criteria of MASLD.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
human health
clinical trial
peritoneal dialysis
prognostic factors
risk assessment
climate change
patient reported